Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.
about
Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping testsGenetic variability in CYP3A5 and its possible consequences.Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.Development and characterization of mucoadhesive in situ nasal gel of midazolam prepared with Ficus carica mucilage.Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adultsIncreased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancerDynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) modelsGenetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers.Dexamethasone as a probe for vinorelbine clearance.Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.Importance of patient selection when determining the significance of the CYP3A5 polymorphism in clinical trials.Clinical implications of CYP3A polymorphisms.Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration.Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines.Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing.PharmGKB summary: very important pharmacogene information for CYP3A5.Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.Association of genotypes of the CYP3A cluster with midazolam disposition in vivo.Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.Pharmacogenomics of CYP3A: considerations for HIV treatment.Overview of pharmacogenetics.Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5.Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.Effect of quercetin on CYP3A activity in Chinese healthy participants.Influence of CYP3A5 and MDR1 genetic polymorphisms on urinary 6 beta-hydroxycortisol/cortisol ratio after grapefruit juice intake in healthy Chinese.Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers.CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer.The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR).In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients.Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients.Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip.Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipients
P2860
Q28260518-3B42FAF6-3E2D-4699-9B2F-C95B6C1FFB97Q30341330-66A661B5-1942-4EFE-9D95-B4ECBD6F3D60Q34278794-FFBCCEBC-FF73-4A97-9D0A-2CD3C51B7BDDQ34280244-68F72A05-A9F9-4220-8D05-0AA3CA7D39F5Q34510611-7F86CA7E-9CB0-4A6F-A62E-6FC241A2915FQ34568130-A0823FC5-C0AB-476E-BB30-D18AF7202C42Q34810573-6C65D7FE-6B4A-4B0F-BE8B-3EF1BDE9F7D9Q35749331-B35273B0-43D8-49F7-9BC9-B58FD3FE190DQ35753588-DAA94447-960E-4F53-BBDF-C2854692894BQ35753607-571B9E3F-15B8-4722-9247-175892DFF135Q35827137-A13628A3-0387-4107-9289-AB70F86F8A02Q35876954-F3713780-20C7-483E-9111-F1A567037BFAQ35918055-44D1C14A-5A6E-4422-B3B3-844C22FFCFEEQ36546247-B3551049-F8FB-4DFB-8760-7FEC86AC8C2AQ36579268-B7193FE2-5524-41CA-92CF-8425CB319EE6Q36884097-92CF86BA-28F9-4AC0-B9D0-38752C88042BQ37076331-30CB33C6-2114-480C-86E0-4E39FDB3714CQ37081741-54746880-FFFA-4331-A4B7-66170AC52435Q37156272-E179DA66-DD1E-4D9C-A502-770667843721Q37359687-75ADC577-6AF7-4186-96CD-CE70E866E6F7Q37369341-C293D136-B3C8-4CEF-A3A0-CD0B9748E6EEQ37419542-B54F1887-EFFD-433F-BFC5-74E9AD9A1BC5Q37938905-17C8B87C-3FB0-47AC-B030-2F2B55526919Q40282075-B2004E52-5EED-4D3E-A911-CB6F4230ACA5Q41328717-A675E901-870E-4F7C-AB00-6BA45132E64BQ42605353-7E35B49E-534C-4491-AB10-A63D56F0C12FQ43160188-BD73068A-8F60-4BF5-8CAC-80D71AAD2A89Q43908823-90147A9E-5D2C-4860-837A-941F026FCB74Q44273424-12DF8010-69C3-4FCD-8F38-834B6EE9DBB7Q44675164-41D0E18E-AC15-4A23-8320-339A140E1DDDQ44892856-5AFEBCEB-E242-4E99-83F9-BEAC58A05638Q44976819-9896FC9D-61C2-4FB5-B9DB-28DC196993A4Q47292609-CF74DC67-E911-4522-9C3C-627676B19841Q48025123-0C0C9B22-4FCC-4B74-B5D8-4F78A35F6C57Q48098073-C3ABC35F-4747-45C7-8A23-0DF867BE0DC4Q48113822-9ECFE948-A505-48BC-A044-7C15E0640EB3Q51297212-31746A5C-4A18-4EA0-BDE3-18417A8C2499Q51590608-10B5B865-1E69-49BC-A62E-D8F30A4A8452Q57269486-B5B16BAB-AAC5-46C9-ADCA-761CBACE6B87
P2860
Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Pharmacokinetics of midazolam ...... th different CYP3A5 genotypes.
@en
Pharmacokinetics of midazolam ...... th different CYP3A5 genotypes.
@nl
type
label
Pharmacokinetics of midazolam ...... th different CYP3A5 genotypes.
@en
Pharmacokinetics of midazolam ...... th different CYP3A5 genotypes.
@nl
prefLabel
Pharmacokinetics of midazolam ...... th different CYP3A5 genotypes.
@en
Pharmacokinetics of midazolam ...... th different CYP3A5 genotypes.
@nl
P356
P1476
Pharmacokinetics of midazolam ...... th different CYP3A5 genotypes.
@en
P2093
Jin-Ding Huang
Pei-Shan Shih
P304
P356
10.1124/DMD.30.12.1491
P577
2002-12-01T00:00:00Z